Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Pump vs Multiple Injections in Type 2 Diabetes (TRICIDIA2)
NCT01889914Phase 4Unknown
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jan 2012
- Primary completion
- Mar 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glulisine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Changes from baseline in insulinoresistance measured by biological tests of hyperinsulinemic euglycemic clamp at 6 months. Status: unknown.
02
Drugs
insulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01889914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889914.